Veracyte (VCYT) stock
NASDAQ
As of the Nov 13, 2026 close (U.S. Eastern)
Events and reference metrics · 1
- Market cap
- $1.96B
- As of Nov 13, 2026
- P/E
- 15.46x
- Trailing twelve months
- P/B
- 1.37x
- Latest reported equity
- P/S
- 3.37x
- Trailing twelve months
- ROE
- 8.9%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
- Market cap
- $1.96B
- As of Nov 13, 2026
- P/E
- 15.46x
- Trailing twelve months
- P/B
- 1.37x
- Latest reported equity
- P/S
- 3.37x
- Trailing twelve months
- ROE
- 8.9%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
15.46x
P/B
1.37x
P/S
3.37x
Earnings and dividend metrics▾
Earnings
EPS
$1.57
Earnings per share
BPS
$17.69
Book value per share
ROE
8.9%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned $1.57 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $17.69 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 8.9%.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 15.2% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $132M+15.2%
$116M
Jul–Sep '24
$132M
Jul–Sep '25
$152M
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Nov 5, 2026.
- Earnings per share increased 58.3% from the same quarter a year earlier.
- Revenue increased 15.2% from the same quarter a year earlier.
- Operating income decreased 26.1% from the same quarter a year earlier.
- Net income increased 68.4% from the same quarter a year earlier.
Filed Nov 5, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Wygant JonathanVP, Chief Accounting Officer · Oct 28, 2026Shares withheld for taxes1,306 shares · $66KAvg. price $50.3141,920 shares held after
- EASTHAM KARINDirector · Oct 27, 2026Open-market sale14,850 shares · $743KAvg. price $50.004910,247 shares held after
- Holstein JensDirector · Oct 27, 2026Open-market sale7,500 shares · $375KAvg. price $5027,471 shares held after
- EASTHAM KARINDirector · Oct 27, 2026Option exercise10,000 shares · $270KAvg. price $27.0125,097 shares held after
- Holstein JensDirector · Oct 27, 2026Option exercise7,500 shares · $265KAvg. price $35.334,971 shares held after
- Bhanji MunaDirector · Oct 19, 2026Open-market sale1,864 shares · $81KAvg. price $43.740,854 shares held after
- Holstein JensDirector · Sep 24, 2026Open-market sale7,500 shares · $353KAvg. price $4727,471 shares held after
- Holstein JensDirector · Sep 24, 2026Option exercise7,500 shares · $265KAvg. price $35.334,971 shares held after
- Leite JohnGlobal Chief Commercial Off · Sep 21, 2026Open-market sale4,015 shares · $161KAvg. price $40124,329 shares held after
- Holstein JensDirector · Sep 14, 2026Open-market sale5,000 shares · $205KAvg. price $40.949427,471 shares held after
- Febbo Phillip G.Chief Scientific & Med Officer · Sep 4, 2026Open-market sale13,110 shares · $564KAvg. price $43.0519
Show 2 price lots
- 10,405 shares × $42.8933$446K
- 2,705 shares × $43.6618$118K
- Chambers RebeccaChief Financial Officer · Sep 4, 2026Open-market sale3,652 shares · $157KAvg. price $43.0981
Show 2 price lots
- 2,477 shares × $42.8059$106K
- 1,175 shares × $43.714$51K
- McGuire AnnieEVP, General Counsel · Sep 4, 2026Open-market sale3,254 shares · $140KAvg. price $43.0891
Show 2 price lots
- 2,154 shares × $42.7916$92K
- 1,100 shares × $43.6718$48K
- Stapley MarcChief Executive Officer · Sep 2, 2026Shares withheld for taxes8,782 shares · $394KAvg. price $44.88432,073 shares held after
- Leite JohnGlobal Chief Commercial Off · Sep 2, 2026Shares withheld for taxes3,961 shares · $178KAvg. price $44.88128,344 shares held after
- Febbo Phillip G.Chief Scientific & Med Officer · Sep 2, 2026Shares withheld for taxes3,639 shares · $163KAvg. price $44.88146,158 shares held after
- Chambers RebeccaChief Financial Officer · Sep 2, 2026Shares withheld for taxes3,603 shares · $162KAvg. price $44.88169,677 shares held after
- McGuire AnnieEVP, General Counsel · Sep 2, 2026Shares withheld for taxes3,215 shares · $144KAvg. price $44.88134,414 shares held after
- Wygant JonathanVP, Chief Accounting Officer · Sep 2, 2026Shares withheld for taxes1,361 shares · $61KAvg. price $44.8843,226 shares held after
- Bhanji MunaDirector · Sep 1, 2026Open-market sale1,864 shares · $80KAvg. price $42.9742,718 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Veracyte (VCYT) stock information
NASDAQ
Veracyte (VCYT) is listed on NASDAQ. Its market capitalization is about $2B. On trailing-twelve-month earnings the P/E ratio is 15.46, and the P/B ratio is 1.37. Return on equity is 8.9%. These figures are computed in-house from official filings and are reference information only.
Veracyte — frequently asked questions
- What is the P/E ratio of Veracyte (VCYT)?
- On a trailing-twelve-month basis, VCYT trades at a P/E ratio of 15.46. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Veracyte?
- VCYT has a market capitalization of about $2B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.